Pilot Study to Determine the Feasibility of Fluconazole for Induction Treatment and Suppression of Relapse of Histoplasmosis in Patients With the Acquired Immunodeficiency Syndrome
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
This NA trial investigates HIV Infections and Histoplasmosis and is currently completed. National Institute of Allergy and Infectious Diseases (NIAID) leads this study, which shows 7 recorded versions since 2026 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed NA
-
Sep 2024 — Sep 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Dec 2021 — Jul 2024 [monthly]
Completed NA
-
Jan 2021 — Dec 2021 [monthly]
Completed NA
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed NA
-
Jan 2017 — Jun 2018 [monthly]
Completed NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- National Institute of Allergy and Infectious Diseases (NIAID)
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Birmingham, United States, Columbus, United States, Houston, United States, Indianapolis, United States, Kansas City, United States, Los Angeles, United States, New York, United States, San Francisco, United States, Springfield, United States, St Louis, United States and 3 more location s